SAFE KIDS Act
Summary
The SAFE KIDS Act (S.3101) is an early-stage bill targeting only surrogacy contracts with foreign adversarial nations. It authorizes zero funding and imposes criminal penalties on surrogacy brokers, which are not identifiable as publicly-traded pure-play entities. No publicly traded company faces direct material revenue impact at this time.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.S.3101 is an early-stage bill with only one sponsor and no companion — negligible passage probability in the near term
- 2.Zero funding authorized — no revenue opportunity for any company
- 3.Scope is extremely narrow — only foreign adversarial surrogacy contracts, leaving the vast majority of the surrogacy and fertility market untouched
- 4.No publicly traded pure-play surrogacy brokers exist to be impacted by the criminal penalties
Market Implications
No market implications for publicly traded securities at this stage. Healthcare and fertility service providers such as Progyny ($PGNY) and CooperCompanies ($COO) remain unaffected due to the bill's narrow focus on surrogacy brokerage with adversarial nations. Monitor for advancement past committee or introduction of a companion bill, which would warrant reassessment.
Full Analysis
-
What happened and its current status: Senator Rick Scott (R-FL) introduced S.3101, the SAFE KIDS Act, on November 4, 2025. It was read twice and referred to the Senate Judiciary Committee. The bill has only one cosponsor and no companion bill in the House. It remains in early-stage committee referral with no further action recorded as of the current date.
-
The money trail: The bill authorizes no funding whatsoever. It establishes no grants, tax credits, loans, or procurement programs. Its mechanism is exclusively prohibitory and penal — it invalidates surrogacy agreements with foreign adversarial nationals and creates criminal penalties for brokers who facilitate them. There is no spending or revenue stream for companies to capture.
-
Structural winners and losers: The bill targets a niche subset of the U.S. surrogacy market — prospective parents from foreign entities of concern as defined by 10 U.S.C. § 4872(f)(2). The explicit scope excludes all domestic surrogacy arrangements and those from non-adversarial nations. No publicly traded pure-play surrogacy brokers exist on U.S. exchanges. Major healthcare and fertility services companies (e.g., Progyny - $PGNY, CooperCompanies - $COO) derive revenue from employer-based fertility benefits and IVF services, which are structurally separate from surrogacy brokerage. The criminal penalties apply to brokers who commercially facilitate invalid agreements, not to physicians, clinics, or broader fertility providers.
-
Competitive landscape: The surrogacy industry in the U.S. is dominated by private agencies, law firms, and boutiques. The bill would not shift market share to any publicly-traded entity.
-
Timeline: The bill requires passage through the Senate Judiciary Committee, floor votes in both chambers, and presidential signature to become law. Given single-sponsor status with no House companion and zero enacted actions since referral, legislative momentum is minimal. No timeline for further action can be projected.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
DELL FEDERAL SYSTEMS L.P: $1.0B Department of Veterans Affairs Contract
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $641M Department of Veterans Affairs Contract
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $773M Department of Veterans Affairs Contract
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $598M Department of Veterans Affairs Contract
Executive Order: Promoting Efficiency, Accountability, and Performance in Federal Contracting
Executive Order: Accelerating Medical Treatments for Serious Mental Illness
ADVANCED TECHNOLOGY INTERNATIONAL: $304M Department of Health and Human Services Contract
Protecting Health Care and Lowering Costs Act of 2025
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.